Bevacizumab or Bevacizumab biosimilar
Preclinical
BeiGeneBevacizumab or Bevacizumab biosimilar is one of 7 therapeutic programs targeting Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerPreclinical
Active, not recruiting
Competition
Competitive Landscape
6 competitors in Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal Cancer
#DrugCompanyPhaseTrials
1Avastin
RochePreclinical
Beyfortus
BeiGenePreclinical
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
Fluoropyrimidine
RochePreclinical
LBL-007
BeiGenePreclinical
Alcestobart
BeiGenePreclinical
Bevacizumab or Bevacizumab biosimilar
BeiGenePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]